High cholesterol often develops through a mixture of genetics, diet, weight, age, medications, and metabolic health. Familial hypercholesterolemia, or FH, follows a different pattern. It causes markedly elevated LDL cholesterol from birth because the body cannot clear LDL normally.
That lifelong exposure makes FH more than an unusually high laboratory result. It represents an inherited cardiovascular condition that can affect several generations of the same family. Fortunately, early identification and sustained treatment can dramatically change its course.
What Makes Familial Hypercholesterolemia Unique?
The key difference involves both the height and duration of LDL exposure. A person who develops an LDL of 190 mg/dL at age 60 has substantial risk. However, someone with FH may have carried a similar level since childhood.
One useful way to understand this risk involves “cholesterol-years.” Just as blood pressure damage reflects pressure over time, LDL risk reflects concentration multiplied by years of exposure. FH starts that clock near birth, often decades before symptoms appear.
| Feature | Familial Hypercholesterolemia | More Common High Cholesterol |
|---|---|---|
| Main driver | Usually an inherited defect in LDL clearance | Often several genetic, metabolic, dietary, and lifestyle influences |
| Timing | High LDL begins in childhood | Often develops or worsens later |
| Typical pattern | Markedly high LDL, often with normal triglycerides | LDL and triglyceride patterns vary |
| Short-term risk score | May underestimate the true lifetime risk | Often helps guide treatment |
| Family implications | Each diagnosis may reveal several affected relatives | Family screening may help, but usually carries less urgency |
| Lifestyle response | Helpful, but rarely sufficient by itself | Sometimes produces a larger share of the needed improvement |
| Treatment approach | Usually early, intensive, and lifelong | Depends more heavily on overall risk and the degree of elevation |
FH does not mean diet and exercise have no value. Rather, a healthy lifestyle cannot fully correct an inherited problem in LDL removal. A person can exercise regularly, maintain a healthy weight, and still have severe LDL elevation.
What Causes FH?
FH affects roughly 1 in 300 people, yet many remain undiagnosed. Changes in the LDLR, APOB, or PCSK9 genes cause most genetically confirmed cases. These genes help the liver recognize, bind, or remove LDL particles from circulation.
Most patients have heterozygous FH, meaning they inherited one disease-causing variant from one parent. Each child of an affected parent generally has a 50% chance of inheriting it. Much rarer homozygous FH involves two affected gene copies and can produce extreme LDL levels during childhood.
Genetics also creates a spectrum rather than two perfectly separate boxes. Some people carry several smaller genetic changes that collectively raise LDL. Others meet strong clinical criteria even when current testing finds no single disease-causing variant.
When Should We Suspect FH?
An untreated LDL cholesterol of 190 mg/dL or higher in an adult should prompt an evaluation. In children, an LDL of 160 mg/dL or higher deserves attention, especially with an affected parent or premature cardiovascular disease in the family. These values raise suspicion, but no single LDL number proves or excludes FH.
Additional clues include:
- A heart attack, coronary disease, stroke, or peripheral artery disease at an unusually young age
- A parent, sibling, or child with very high LDL cholesterol
- Several relatives with premature cardiovascular disease
- Tendon xanthomas, which are firm cholesterol deposits in tendons
- A corneal arcus at a young age, especially before age 45
- LDL cholesterol above approximately 400 mg/dL, which raises concern for homozygous FH
How Do We Diagnose FH?
A thoughtful diagnosis combines several pieces of evidence. Clinicians review untreated LDL levels, family history, premature cardiovascular events, physical findings, and genetic results when available. Formal tools such as the Dutch Lipid Clinic Network criteria can organize these findings in adults.
Before labeling the condition, clinicians should also look for secondary causes. Hypothyroidism, nephrotic syndrome, cholestatic liver disease, pregnancy, and certain medications can raise cholesterol. Correcting these conditions may clarify how much LDL elevation comes from an inherited disorder.
Genetic testing can confirm the diagnosis and make family screening more precise. However, a negative result does not eliminate FH because current panels do not detect every relevant cause. Conversely, LDL above 190 mg/dL does not automatically mean monogenic FH.

One Diagnosis Can Protect an Entire Family
FH changes the unit of care from one person to one family. After identifying an affected individual, clinicians should offer cholesterol testing to parents, siblings, and children. When genetic testing finds a specific variant, relatives can test for that same variant.
This stepwise process, called cascade screening, often identifies relatives before symptoms develop. Universal cholesterol screening between ages 9–11 also helps find children whose family history remains incomplete or unknown. Earlier screening may begin around age two when close relatives have FH or premature cardiovascular disease.
Looking Beyond LDL Cholesterol Alone
LDL remains central, but comprehensive care examines the whole cardiovascular picture. Non-HDL cholesterol and apolipoprotein B help estimate the total burden of atherogenic particles. Lipoprotein(a), or Lp(a), deserves at least one measurement because it adds a separate inherited risk that often travels through families.
Blood pressure, smoking, diabetes, kidney disease, inflammation, sleep, activity, and body composition also shape the final outcome. These factors do not cause FH, but they can accelerate or slow the disease around it. Imaging may refine risk in selected adults, although a coronary calcium score of zero does not erase lifelong LDL exposure or the need to treat FH.
How Do We Treat Familial Hypercholesterolemia?
Treatment aims to lower LDL early, substantially, and sustainably. Current expert guidance generally favors at least a 50% reduction. For adults with heterozygous FH, a common goal is below 70 mg/dL without established cardiovascular disease and below 55 mg/dL with it. Age, plaque burden, other conditions, treatment response, and tolerance still shape the final target.
| Treatment | Approximate LDL Reduction | Common Role in FH |
|---|---|---|
| High-intensity statin | About 50% or more | Foundation of adult treatment |
| Ezetimibe | About 15–25% additional lowering | Common first addition to a statin |
| PCSK9 antibody | About 50–60% additional lowering | Powerful option when LDL remains above goal |
| Inclisiran | About 50% lowering | Long-acting PCSK9 pathway treatment with twice-yearly maintenance dosing |
| Bempedoic acid | About 15–25% lowering | Oral option for added lowering or statin intolerance |
| Specialized HoFH therapy | Varies by treatment | Evinacumab, lomitapide, and LDL apheresis for severe disease |
Many patients need combination therapy because one medication cannot overcome the full genetic effect. Statins increase the liver’s ability to remove LDL, while ezetimibe reduces intestinal cholesterol absorption. PCSK9-targeted treatments preserve LDL receptors, and bempedoic acid reduces cholesterol production through another liver pathway.
Homozygous FH requires specialized care as early as possible. Some patients have very little LDL-receptor function, so ordinary treatments provide limited benefit. Evinacumab and lomitapide can lower LDL through pathways that do not depend entirely on the LDL receptor. LDL apheresis physically removes LDL from the blood and may remain essential.
Lifestyle still supports every treatment plan. A Mediterranean-style eating pattern, lower saturated fat intake, regular activity, healthy sleep, weight management, and smoking avoidance reduce the broader cardiovascular burden. However, supplements and lifestyle changes should support effective medication rather than delay it.
Children, Pregnancy, and Other Special Situations
Children with FH usually need treatment before adulthood because artery exposure has already begun. Clinicians commonly consider statin therapy around ages 8–10, then adjust treatment according to LDL response, family history, and disease severity. This approach protects future health rather than treating a childhood symptom.
Pregnancy requires advance planning because cholesterol naturally rises and several medications usually pause. Most pregnant patients stop statins, although specialists may consider them in exceptional, very-high-risk situations. Bile acid sequestrants and LDL apheresis offer alternatives in selected cases, especially with homozygous FH or established cardiovascular disease.
Common Patient Patterns
- Case 1 — Severe LDL Despite a Healthy Lifestyle: A 38-year-old runner has an untreated LDL of 224 mg/dL. His father had a heart attack at 47. The pattern strongly supports FH, so treatment begins without blaming diet or weight.
- Case 2 — A Secondary Cause That Resembles FH: A 46-year-old woman has an LDL of 201 mg/dL and marked hypothyroidism. Thyroid treatment lowers her LDL substantially. Her remaining pattern no longer supports FH, which shows why diagnosis requires more than one number.
- Case 3 — FH Below the Classic Threshold: A 34-year-old woman has an LDL of 174 mg/dL, but her treated mother has FH. Genetic testing finds the same LDLR variant. Her value below 190 mg/dL does not exclude the condition.
- Case 4 — A Child Protects the Family: Universal screening finds high LDL in a healthy 10-year-old boy. Further testing identifies FH in his mother and two siblings. One childhood result creates a preventive opportunity across two generations.
- Case 5 — Extreme LDL in Early Childhood: A six-year-old develops tendon and skin cholesterol deposits with an LDL above 500 mg/dL. Evaluation confirms homozygous FH. He needs immediate combination therapy and care from a specialized lipid center.
Why Holistic, Individualized Care Matters
FH demands urgency without losing perspective. LDL exposure drives the central risk, but no two patients carry the same complete picture. One person may also have high Lp(a), hypertension, or diabetes, while another has reassuring imaging and excellent metabolic health.
A smart strategy therefore connects diagnosis, family screening, treatment intensity, medication tolerance, and the broader cardiovascular profile. This balanced approach avoids two errors: minimizing a lifelong genetic risk or reducing the entire person to one cholesterol value.
The Takeaway
Familial hypercholesterolemia differs from ordinary high cholesterol because it begins early, persists throughout life, and travels through families. The present LDL level matters, but the accumulated exposure matters even more. Early diagnosis changes the trajectory, while cascade screening extends that benefit to relatives who may feel completely well.
At our practice in Montgomery County, Maryland, and through virtual care, we evaluate severe cholesterol from multiple angles. Personalized lipid care connects LDL, apoB, non-HDL cholesterol, Lp(a), genetics, family history, imaging, and overall metabolic health to create a meaningful long-term prevention plan.
- Familial Hypercholesterolemia: Challenges for a High-Risk Population: JACC Focus Seminar 1/3. Choi D, Malick WA, Koenig W, Rader DJ, Rosenson RS. Journal of the American College of Cardiology. 2023.
- Familial Hypercholesterolemia: JACC Focus Seminar 4/4. Brandts J, Ray KK. Journal of the American College of Cardiology. 2021.
- Genetic Testing for Heritable Cardiovascular Diseases in Pediatric Patients: A Scientific Statement From the American Heart Association. Landstrom AP, Kim JJ, Gelb BD, et al. Circulation: Genomic and Precision Medicine. 2021.
- Advances in Familial Hypercholesterolaemia in Children. Reijman MD, Kusters DM, Wiegman A. The Lancet Child & Adolescent Health. 2021.
- Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. Santos RD, Ruzza A, Hovingh GK, et al. NEJM. 2020.
- The Familial Hypercholesterolaemia Phenotype: Monogenic Familial Hypercholesterolaemia, Polygenic Hypercholesterolaemia and Other Causes. Mariano C, Alves AC, Medeiros AM, et al. Clinical Genetics. 2020.
- Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Journal of the American College of Cardiology. 2020.
- Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia. Trinder M, Li X, DeCastro ML, et al. Journal of the American College of Cardiology. 2019.
- Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. Sturm AC, Knowles JW, Gidding SS, et al. Journal of the American College of Cardiology. 2018.
- Familial Hypercholesterolaemia. Defesche JC, Gidding SS, Harada-Shiba M, et al. Nature Reviews Disease Primers. 2017.
- Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia. Lozano P, Henrikson NB, Dunn J, et al. JAMA. 2016.
- The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Gidding SS, Champagne MA, de Ferranti SD, et al. Circulation. 2015.
- The Severe Hypercholesterolemia Phenotype: Clinical Diagnosis, Management, and Emerging Therapies. Sniderman AD, Tsimikas S, Fazio S. Journal of the American College of Cardiology. 2014.
About Dr. Gerti Tashko, MD
Dr. Gerti Tashko, MD, is an endocrinologist in Montgomery County, Maryland. He is uniquely quadruple board-certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice delivers root-cause-focused metabolic and endocrine care, available virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to improve long-term health.



